aap Implantate Balance Sheet Health
Financial Health criteria checks 4/6
aap Implantate has a total shareholder equity of €9.4M and total debt of €236.0K, which brings its debt-to-equity ratio to 2.5%. Its total assets and total liabilities are €14.0M and €4.6M respectively.
Key information
2.52%
Debt to equity ratio
€236.00k
Debt
| Interest coverage ratio | n/a |
| Cash | €576.00k |
| Equity | €9.38m |
| Total liabilities | €4.60m |
| Total assets | €13.98m |
Recent financial health updates
Is aap Implantate (ETR:AAQ1) Weighed On By Its Debt Load?
Apr 04
Here's Why aap Implantate (ETR:AAQ1) Can Afford Some Debt
Dec 06Is aap Implantate (ETR:AAQ1) Using Too Much Debt?
Aug 23aap Implantate (ETR:AAQ1) Is Carrying A Fair Bit Of Debt
May 10Recent updates
Investors Give aap Implantate AG (ETR:AAQ1) Shares A 26% Hiding
Jun 15One Analyst Just Shaved Their aap Implantate AG (ETR:AAQ1) Forecasts Dramatically
Aug 20Is aap Implantate (ETR:AAQ1) Weighed On By Its Debt Load?
Apr 04Here's Why aap Implantate (ETR:AAQ1) Can Afford Some Debt
Dec 06Is aap Implantate (ETR:AAQ1) Using Too Much Debt?
Aug 23aap Implantate (ETR:AAQ1) Is Carrying A Fair Bit Of Debt
May 10Financial Position Analysis
Short Term Liabilities: AAQ1's short term assets (€7.7M) exceed its short term liabilities (€3.2M).
Long Term Liabilities: AAQ1's short term assets (€7.7M) exceed its long term liabilities (€1.4M).
Debt to Equity History and Analysis
Debt Level: AAQ1 has more cash than its total debt.
Reducing Debt: AAQ1's debt to equity ratio has reduced from 3.2% to 2.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AAQ1 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AAQ1 has less than a year of cash runway if free cash flow continues to grow at historical rates of 27.2% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/10 08:16 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
aap Implantate AG is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Percy Leung | DBS Bank Ltd |
| Hans Bjorn Bostrom | Edison Investment Research |
| Alexander Galitsa | Hauck Aufhäuser Investment Banking |